<DOC>
	<DOCNO>NCT00753792</DOCNO>
	<brief_summary>This phase IV , multicenter , randomize , double blind clinical trial . The investigator study 48 patient remit relapse multiple sclerosis ( MS ) experience moderate severe attack receive immunomodulatory therapy . Patients randomly assign one two group .</brief_summary>
	<brief_title>Oral Corticotherapy Megadoses Treat Multiple Sclerosis During Relapse</brief_title>
	<detailed_description>This multicenter , randomize , double blind clinical trial test whether oral methylprednisolone ( MP ) inferior intravenous methylprednisolone treatment multiple sclerosis ( MS ) relapse term clinical radiological efficacy . Patients randomly assign one follow two group . Group A : methylprednisolone 1.000 mg/day intravenous administer three day + placebo methylprednisolone orally administer Group B : methylprednisolone 1.250 mg/day orally administer three day + placebo methylprednisolone intravenously administer . Clinical visit conduct 7 , 28 90 day treatment start .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . To diagnosed MS Remittent Recurrent accord Mc Donald 20052 criterion . 2 . To EDSS 0 5 relapse . 3 . The symptom begin least one month previous stability . 4 . The symptom start maximum 15 day inclusion . 5 . The patient capable adequate communication investigator carry clinical trial requisite . 6 . To allow immunomodulatory therapy ( IFNB /AG ) . 7 . To capable willing ingest medication . 1 . First inflammatory neurological episode ( relapse ) . 2 . Multiple sclerosis secondary progressive primary progressive . 3 . The symptom go less 24 hour . 4 . To treatment treated corticoid three month . 5 . Patients treatment immunosuppressor ( azathioprine , mitoxantrone , ciclofosfamide ... ) 6 . Pregnancy breastfeed woman fertile age n't use contraceptive measurement . 7 . Illnesses contraindication treatment corticoid . 8 . Antecedents serious adverse effect hypersensitive related study medication . 9 . Patients wouldnÂ´t able perform periodic RMN exploration , patient collaborative need anesthesia . 10 . Patients intolerance lactose . 11 . Patients allergy contrast use RMN . 12 . Patients chronic kidney disease . 13 . Patients treatment natalizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>relapse</keyword>
	<keyword>methylprednisolone</keyword>
</DOC>